Russia finishes 2nd stage of Sputnik V Light vaccine
The Gamaleya Research Institute of Epidemiology and Microbiology has finished the second phase of its Sputnik V Light coronavirus vaccine and submitted the necessary documentation to the health regulators, Russian Health Minister Mikhail Murashko (pictured) stated on Friday.
He added that the Vektor State Research Center of Virology and Biotechnology, which developed the EpiVacCorona vaccine, also submitted the documentation to Rospotrebnadzor, which will now assess if the jab can be recommended for use in people over 60 years of age.
EpiVacCorona was the second vaccine approved by the Russian health authorities, while the Sputnik V Light is a modified single-dose version of the country’s first jab Sputnik V, and was initially touted as a way to help countries with high infection rates curb the number of deaths and serious illnesses.
Get involved!
Comments